Skip to main content
. 2020 Jul 15;12(7):1905. doi: 10.3390/cancers12071905

Figure 4.

Figure 4

Comparative efficacy for progression-free survival (PFS) among the five therapeutic regimens (Niv+Ipi, Pem+PBC, Pem, Niv, and PBC) in patients with programmed cell death ligand 1 (PD-L1) expression levels of 50% or more. Comparisons were expressed as Treatment A versus Treatment B. Data are expressed in terms of hazard ratio (HR) and 95% credible intervals (CrIs); Niv, nivolumab; PBC, platinum-based chemotherapy; Pem, pembrolizumab; Ipi, ipilimumab.